Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

US10357514B2 · kind B2 · utility

Assignees

• The Trustees of the University of Pennsylvania · US
• Novartis AG · CH

Inventors

• Carl H. June · Yeadon, US
• David L. Porter · Springfield, US
• Marcela Maus · Lansdowne, US
• Mariusz A. Wasik · Ardmore, US
• Saar Gill · Philadelphia, US
• Joseph A. Fraietta · Cherry Hill, US
• Marco Ruella · Ardmore, US
• John C. Byrd · Columbus, US
• Jason A. Dubovsky · Columbus, US
• Amy J. Johnson · Dublin, US
• Natarajan Muthusamy · Galloway, US
• Saad Kenderian · Philadelphia, US
• Joan Mannick · Cambridge, US
• David Glass · Cambridge, US
• Leon Murphy · Cambridge, US
• Jennifer Brogdon · Cambridge, US
• William R. Sellers · Sharon, US

Key dates

• Filing date: Apr 7, 2015
• Grant date: Jul 23, 2019
• Expiry date: Apr 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.